Drugs / CIML-NK cell therapy
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07011004 | May 2025 → May 2028 expected | acute myeloid leukemia | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CIML-NK cell therapy | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07011004 ↗ |
| Modality | Cell therapy | “CIML-NK cell therapy as an intravenous (IV) infusion” NCT07011004 ↗ |
| Route | Intravenous | “CIML-NK cell therapy as an intravenous (IV) infusion” NCT07011004 ↗ |